Achieve Life Sciences (NASDAQ:ACHV) and Oruka Therapeutics (NASDAQ:ORKA) Head to Head Survey

Oruka Therapeutics (NASDAQ:ORKA) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.

Profitability

This table compares Oruka Therapeutics and Achieve Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-24.96%	-21.22%
Achieve Life Sciences	N/A	-108.30%	-65.20%

Volatility & Risk

Oruka Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.

Insider and Institutional Ownership

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 22.7% of Oruka Therapeutics shares are held by company insiders. Comparatively, 2.0% of Achieve Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Oruka Therapeutics and Achieve Life Sciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$5.34 million	($5.79)	-2.06
Achieve Life Sciences	N/A	N/A	-$29.82 million	($1.23)	-2.24

Achieve Life Sciences is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Oruka Therapeutics and Achieve Life Sciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	7	2	3.22
Achieve Life Sciences	0	0	3	2	3.40

Oruka Therapeutics presently has a consensus target price of $39.86, indicating a potential upside of 233.53%. Achieve Life Sciences has a consensus target price of $15.75, indicating a potential upside of 472.73%. Given Achieve Life Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe Achieve Life Sciences is more favorable than Oruka Therapeutics.

Summary

Oruka Therapeutics beats Achieve Life Sciences on 7 of the 11 factors compared between the two stocks.

About Oruka Therapeutics

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

About Achieve Life Sciences

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.